linjc16/ctgov huggingface dataset:
Incidence of Different Surgical Technics for Colorectal Deep Infiltrating EndoMetriosis on the Post-operative Fertility and Pregnancy Outcomes

Study Overview
=================
Brief Summary
-----------------
Endometriosis is a disease that is very present on the current media scene. Its symptoms are very nonspecific and numerous. (dysmenorrhea, dyspareunia, dyschezia, urinary functional signs, infertility, chronic pelvic pain, etc.) Its prevalence is estimated at 10% of women and 20% of them have deep pelvic endometriosis. Colorectal lesions involving the rectosigmoid junction and the rectum represent the most severe forms and affect 5.3 to 12% of patients with deep pelvic endometriosis. Endometriosis is found in 20 to 50% of patients consulting for infertility and the rate of spontaneous pregnancy in patients with deep endometriosis is estimated to be between 8.7 and 13%. Surgery appears to improve fertility in women. However, several surgical techniques for deep endometriosis at the digestive level have been described, conservative or radical, without any having demonstrated its superiority both in terms of symptoms and fertility. The aim of this study was to evaluate the incidence of different surgical technics (shaving vs. bowel resection) on post-operative fertility among patients with bowel deep infiltrating endometriosis and the pregnancy outcome

Official Title
-----------------
Incidence of Different Surgical Technics for Colorectal Deep Infiltrating EndoMetriosis on the Post-operative Fertility and Pregnancy Outcomes

Conditions
-----------------
Endometriosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult woman (≥18 years old). woman with a desire to become pregnant and who had undergone surgery for the management of deep digestive endometriosis between September 01, 2009 and October 31, 2016. Woman who has not expressed, after information, the reuse of her data for the purposes of this research. Exclusion Criteria: Woman who expressed her opposition to participating in the study Woman who had undergone a surgical intervention for the management of deep digestive endometriosis between September 01, 2009 and October 31, 2016 and having no desire to become pregnant Woman under safeguard of justice Woman under guardianship or guardianship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retrospective analysis of the rate of occurrence of pregnancy postoperatively. |  | Files analysed retrospectily from September 1st, 2009 to October 31, 2016 will be examined | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
colorectal endometriosis, deep infiltrating endometriosis, fertility, surgical technics in endometriosis
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety and effectiveness of 2 drugs (AmBisome versus voriconazole) in treating fungal infections. Immunocompromised patients, especially those with persistent fever and neutropenia, are at a high risk of developing deeply invasive, life-threatening fungal infections with Candida, Aspergillus, and other opportunistic fungal pathogens. The risk of fungal infection increases in direct proportion with severity of neutropenia and duration of fever. Antifungal therapy, therefore, is an important step in the amelioration of fungal disease.

Detailed Description
-----------------
Patients are first split into groups to receive either voriconazole or AmBisome. Both drugs are given through a vein (IV) for at least 3 days. At the conclusion of 3 days, the voriconazole patients are then switched to oral voriconazole. The AmBisome patients continue with IV AmBisome. Both groups continue treatment until blood counts increase and fever subsides.

Official Title
-----------------
A Randomized, Open Label, Comparative, Multicenter Trial of Voriconazole Vs. AmBisome for Empirical Antifungal Therapy in Immunocompromised Patients With Persistent Fever and Neutropenia

Conditions
-----------------
Neutropenia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: You may be eligible for this study if you: Are at least 12 years of age. Are hospitalized with low white blood cell counts. Have received at least 96 hours of IV antibiotics. Have an oral temperature (or equivalent) of 38.0 C (100.4 F) or greater within the 24 hours before the study starts. Are not pregnant or breast-feeding. Agree to use a barrier method of contraception (e.g., a condom) during the study Exclusion Criteria: You will not be eligible for this study if you: Have a serious fungal infection. Have a history of an allergic reaction to antifungal agents. Are taking certain medications which may interfere with the study drug. Are participating in a clinical trial of any investigational drug. Have previously participated in this trial. Have any conditions which could affect your safety, make evaluation of response difficult, or make it unlikely that you can complete the course of therapy.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

Study Overview
=================
Brief Summary
-----------------
Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas Trial with medicinal product

Conditions
-----------------
Crohn's Disease

Intervention / Treatment
-----------------
* Drug: QAX567


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: - diagnosis of Crohn's disease > 6 month with fistula - at least 1 ineffective fistula treatment in the past Exclusion criteria: - TNF a antibody treatment failed in the past - planned surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: QAX567|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| complete closure of fistula |  |  |
Atypical Fracture Cohort Study

Study Overview
=================
Brief Summary
-----------------
Osteoporosis is a disease characterized by increased bone fragility and deteriorating bone micro-architecture. The main consequence of osteoporosis is low-trauma fractures, most often of the hip, spine and wrist. Recently, another type of low-trauma fracture, atypical femur fractures (AFFs), have received much attention. Little is known of the cause of these debilitating fractures; however, they have been associated with long term bisphosphonate use. What we currently know about AFFs is based on case reports or small case series, or studies using administrative databases or secondary analyses of bisphosphonate trials. While these reports provide some preliminary information on the relationship between long term bisphosphonate exposure and AFFs, detailed clinical data are absent. As we have established a network of specialists across southern Ontario our group is in a position to collect meaningful information on a larger group of patients who have experienced these debilitating fractures into a centralized AFF registry.

Official Title
-----------------
Atypical Femur Fracture Ontario Cohort Registry

Conditions
-----------------
Atypical Subtrochanteric Fracture, Osteoporosis With AFf, Atypical Femur Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over the age of 20; Patients who have experienced an incomplete AFF that satisfies the diagnostic criteria as set forth by the American Society of Bone and mineral Research (ASBMR) International Task Force on AFFs or a low (or no) trauma fracture that mimics the features described above at other sites. Exclusion Criteria: Peri-prosthetic fractures; High trauma fractures; Pathological fractures secondary to metastases or metabolic bone diseases other than osteoporosis.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Atypical femur fracture cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prospectively identify and diagnose atypical fracture patients in Ontario | The objective of this exploratory study is to identify and diagnose AFF patients | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Examine risk factors and predictors for AFFs | This exploratory study will examine risk factors and predictors for AFFs | baseline |
The Association of Cognitive Distortions and NCDs Among Users of Medical Internet Resources

Study Overview
=================
Brief Summary
-----------------
Currently, medical Internet resources are popular among the population of most countries, including Russia. So its can be used as a platform for mass measures of prevention. Now we can receive a lot of information about socio-demographic characteristics, risk factors and the presence of chronic non-infectious diseases among users of medical Internet resources. And these knowledges are necessary to create effective online interventions for prevention of the most common diseases. We have enough resources to identify and control risk factors for chronic non-infectious diseases. But adherence to doctor's recommendations remains at a low level. Working with cognitive biases is one of the points of application for increasing adherence to treatment and the rules of a healthy lifestyle. Certain groups of patients have special cognitive biases. We assume that creation a typical portrait of a patient can reveal relationships and factors the variant of cognitive biases. This information may help to more effectively carry out preventive work with users of medical Internet resources, forming the correct patterns of perception and thereby improving adherence to the doctor's recommendations.

Official Title
-----------------
The Association of Cognitive Distortions and NCDs Among Users of Medical Internet Resources

Conditions
-----------------
Cognitive Biases, Non-infecious Chronic Disease

Intervention / Treatment
-----------------
* Other: Questionnaire CMQ


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: User of medical Internet resources older 18 years Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Users of medical internet resources<br>This group includes people older 18 years who are looking for medical information at the Internet-resources | Other: Questionnaire CMQ<br>* The questionnaire is used to diagnose cognitive distortions. It includes 50 items to identify 10 the most common cognitive biases.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The questionnaire Cognitive Mistakes Questionnaire | The questionnaire consist of 10 blocks on various types of cognitive distortions. Each block includes 5 questions. The maximum score of scale is 5 point, the minimum score of scale is 0 points. The maximum score means the severity of certain cognitive distortion | from 1 February to 1 March 2022 |
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada

Study Overview
=================
Brief Summary
-----------------
This is a non-interventional, cross-sectional survey study to evaluate the effectiveness of the Additional Risk Minimization Measures for Fibristal among Patients in Canada.

Detailed Description
-----------------
Data will be collected via web-based data capture and paper surveys depending on patient preference. The survey will be conducted in a single wave over 6 months. All data will be maintained in compliance with local regulations.

Official Title
-----------------
A Cross-sectional Study Among Patients in Canada to Assess Awareness and Knowledge of the Fibristal Patient Alert Card

Conditions
-----------------
Uterine Fibroids

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have received Fibristal within 6 months of completing the survey. Patients who have provided permission to share their responses in aggregate with Health Canada. Patients who have provided informed consent for their participation in the survey. Exclusion Criteria: Patients who participated in the cognitive pre-testing of the survey questionnaire to be used for the study. Patients who have been direct employees of Allergan, ICON, Health Canada, or Professional Targeted Marketing (PTM) within the past year.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentages of patients with correct responses to the knowledge related questions based on the contents of the Fibristal Patient Alert Card. | Correct responses to knowledge-related questions (i.e, potential of fibristal to cause liver injury, signs and symptoms of liver problems, and what to do in case of signs and symptoms of liver problems.) | 18 - 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentages of patients that recall recieving and using the Fibristal Patient Alert Card | Receipt and use of the Fibristal Patient Alert Card, | 18 - 24 months | 
| Percentage of patients that recall their HCPs' ordering of required liver function tests in accordance with the recommendations in the aRMM/CPM | Timing and frequency of liver testing conducted by the patients's HCP | 18 - 24 months |
Reproducibility Study of Over Active Bladder Symptom Score [OABSS]

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the reproducibility of over active bladder symptom score (OABSS) in Asian countries.

Official Title
-----------------
Reproducibility Study of OABSS and Its Response to Treatment - Part 1: Reproducibility -

Conditions
-----------------
Overactive Bladder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Symptoms OAB for 3 months or longer At least 1 urgency episode in last 3 days Symptoms of OAB as verified by the screening 3-day bladder diary, defined by: Number of micturition ≥8 times/day Number of urgency episode in 3 days ≥1 Exclusion Criteria: Indwelling catheters or practicing intermittent self-catheterization Symptomatic urinary tract infection, chronic inflammation Diabetic neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OABSS |  | Weeks of 0 and 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 3-day micturition diary |  | 2 times in 2-week interval | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
OABSS
Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients

Study Overview
=================
Brief Summary
-----------------
This is an evaluation of celiac-specific patient reported outcome instruments in celiac disease patients.

Official Title
-----------------
Clinical Evaluation of Three Celiac Disease-Specific Patient Reported Outcome Instruments in Established and Newly Diagnosed Celiac Disease Patients

Conditions
-----------------
Celiac Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: History of biopsy proven celiac disease Adherence to a gluten-free diet (established patients only) TG2 negative (established patients only) TG2 positive (newly diagnosed patients only) Signed informed consent Exclusion Criteria: History of IgE-mediated reactions to gluten Significant laboratory abnormalities History of untreated or GI disease Positive pregnancy test Any medical condition which could adversely affect study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Gluten challenge<br>Gluten containing or gluten-free study food in established celiac disease patients | |
| Observation<br>Observation in newly diagnosed celiac disease patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in symptoms using patient reported outcome instruments | Sensitivity of the patient reported outcome instruments to detect change over time in celiac disease symptoms with and without a gluten challenge | 8 and 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety - incidence of adverse events | Safety will be evaluated by incidents of adverse events including clinical significant laboratory evaluations and serious adverse events | 8 and 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Celiac Disease, Coeliac Disease, Celiac Sprue, Keilakia Disease
At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults

Study Overview
=================
Brief Summary
-----------------
This study is aimed at examining the BCVA from try-on glasses constructed from measurements from the EyeQue VisionCheck.

Detailed Description
-----------------
This study is aimed at examining the BCVA from try-on glasses constructed from measurements from the EyeQue VisionCheck. The refraction measurements that users obtain from the VisionCheck are from testing at-home and without additional guidance other than that normally provided to those purchasing the device.

Official Title
-----------------
An Open Label Study to Evaluate At-home Testing Refraction Results With Best Corrected Visual Acuity (BCVA) Outcomes in Adults

Conditions
-----------------
Visual Impairment, Myopia, Hyperopia, Astigmatism

Intervention / Treatment
-----------------
* Device: With Try-on glasses


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female Ages 30+ Had purchased an EyeQue refraction device. Obtained EGN's from the EyeQue refraction device. Ordered Try-On glasses based on EyeQue EyeGlass Numbers. Allow use for this study the VisionCheck refraction and try-on glasses measurements, taken prior to study participation. Subject Exclusion Criteria, Subjects that by self-report: Do not have a command of the English language. Lack the ability to follow instructions. Lack binocular vision. Are Color-blind.

Ages Eligible for Study
-----------------
Minimum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Interventional Model Description: Subjects who had previously tested with an EyeQue ophthalmic refraction device and ordered try-on glasses will be asked to measure their visual acuity with and without their try-on glasses.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Without Try-on glasses<br>Subjects will be asked to measure their visual acuity without their try-on glasses | Device: With Try-on glasses<br>* Subjects will be asked to measure their visual acuity with their try-on glasses<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual Acuity with and without try-on glasses | Visual Acuity with and without try-on glasses | Visit 1: Day 0 |